Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio para evaluar los eventos adversos, el cambio en la actividad de la enfermedad y cómo el risankizumab intravenoso y subcutáneo se mueve a través del cuerpo de participantes pediátricos con enfermedad de Crohn activa de moderada a grave (RISE)

15 de octubre de 2026 actualizado por: AbbVie

Un estudio multicéntrico de fase 3 para evaluar la farmacocinética, la eficacia y la seguridad de risankizumab con inducción abierta, mantenimiento doble ciego aleatorizado y períodos de extensión a largo plazo en sujetos pediátricos (2 a < 18 años de edad) con Enfermedad de Crohn moderada a gravemente activa

Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies.

Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide.

Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Tipo de estudio

Intervencionista

Inscripción (Estimado)

110

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Bavaria
      • Munich, Bavaria, Alemania, 80337
        • Reclutamiento
        • Dr. von Haunerschen Kinderspital /ID# 255577
    • North Rhine-Westphalia
      • Münster, North Rhine-Westphalia, Alemania, 48149
        • Reclutamiento
        • Universitaetsklinikum Muenster /ID# 256762
      • Plovdiv, Bulgaria, 4002
        • Reclutamiento
        • UMHAT Sveti Georgi EAD /ID# 255386
      • Sofia, Bulgaria, 1606
        • Terminado
        • Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384
      • Varna, Bulgaria, 9009
        • Reclutamiento
        • UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358
      • Brussels, Bélgica, 1020
        • Reclutamiento
        • Hospital Universite Enfants Reine Fabiola /ID# 255112
      • Liège, Bélgica, 4000
        • Reclutamiento
        • Groupe Sante CHC - Clinique du MontLegia /ID# 255620
    • Antwerpen
      • Edegem, Antwerpen, Bélgica, 2650
        • Reclutamiento
        • Uza /Id# 255114
    • Brussels Capital
      • Brussels, Brussels Capital, Bélgica, 1200
        • Reclutamiento
        • Cliniques Universitaires UCL Saint-Luc /ID# 255108
      • Jette, Brussels Capital, Bélgica, 1090
        • Reclutamiento
        • Universitair Ziekenhuis Brussel /ID# 255109
    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Bélgica, 3000
        • Reclutamiento
        • Universitair Ziekenhuis Leuven /ID# 255098
    • Alberta
      • Calgary, Alberta, Canadá, T3B 6A8
        • Reclutamiento
        • Alberta Children's Hospital /ID# 255357
      • Edmonton, Alberta, Canadá, T6G 1C9
        • Reclutamiento
        • Edmonton Clinic Health Academy /ID# 255361
    • British Columbia
      • Vancouver, British Columbia, Canadá, V6H 3V4
        • Reclutamiento
        • BC Children's Hospital /ID# 255359
    • Ontario
      • London, Ontario, Canadá, N6A 5W9
        • Reclutamiento
        • London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598
    • Praha 17
      • Prague, Praha 17, Chequia, 128 00
        • Terminado
        • Vseobecna Fakultni nemocnice v Praze /ID# 256096
    • Praha 5
      • Prague, Praha 5, Chequia, 150 06
        • Terminado
        • Fakultni nemocnice Motol a Homolka /ID# 256547
      • Daegu, Corea del Sur, 41404
        • Reclutamiento
        • Kyungpook National University Chilgok Hospital /ID# 255817
    • Seoul Teugbyeolsi
      • Seoul, Seoul Teugbyeolsi, Corea del Sur, 03080
        • Reclutamiento
        • Seoul National University Hospital /ID# 255318
      • Seoul, Seoul Teugbyeolsi, Corea del Sur, 06351
        • Reclutamiento
        • Samsung Medical Center /ID# 255284
      • Seoul, Seoul Teugbyeolsi, Corea del Sur, 03722
        • Reclutamiento
        • Yonsei University Health System - Severance Hospital /ID# 256976
      • Madrid, España, 28009
        • Terminado
        • Hospital Infantil Universitario Nino Jesus /ID# 255012
      • Málaga, España, 29011
        • Reclutamiento
        • Hospital Regional Universitario de Malaga /ID# 257553
    • A Coruna
      • Ferrol, A Coruna, España, 15405
        • Reclutamiento
        • Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85016-7710
        • Reclutamiento
        • Phoenix Children's Hospital /ID# 255766
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72202
        • Terminado
        • Arkansas Children's Hospital /ID# 255762
    • California
      • Oakland, California, Estados Unidos, 94609
        • Reclutamiento
        • UCSF Benioff Children's Hospital - Oakland /ID# 258327
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Reclutamiento
        • Children's Hospital Colorado - Aurora /ID# 255764
    • Florida
      • Orlando, Florida, Estados Unidos, 32806-1141
        • Reclutamiento
        • Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Reclutamiento
        • Indiana University Health Riley Hospital for Children /ID# 256454
    • Massachusetts
      • Waltham, Massachusetts, Estados Unidos, 02451
        • Reclutamiento
        • Massachusetts General Hospital - Mass General Waltham /ID# 255767
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55413-2195
        • Reclutamiento
        • MNGI Digestive Health, P. A. /ID# 255366
    • New Jersey
      • Morristown, New Jersey, Estados Unidos, 07960
        • Reclutamiento
        • Goryeb Childrens Hospital /ID# 256452
    • New York
      • New York, New York, Estados Unidos, 10029
        • Reclutamiento
        • Icahn School of Medicine at Mount Sinai /ID# 254880
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195
        • Reclutamiento
        • Cleveland Clinic - Cleveland /ID# 256453
        • Contacto:
          • Site Coordinator
          • Número de teléfono: 216-636-2007
      • Paris, Francia, 75015
        • Reclutamiento
        • AP-HP - Hopital Necker /ID# 255608
    • Centre-Val de Loire
      • Tours, Centre-Val de Loire, Francia, 37044
        • Reclutamiento
        • CHRU Tours - Hopital Gatien de Clocheville /ID# 255052
    • New Aquitaine
      • Bordeaux, New Aquitaine, Francia, 33076
        • Reclutamiento
        • Chu Bordeaux - Hopital Pellegrin /ID# 257060
    • Occitanie
      • Toulouse, Occitanie, Francia, 31059
        • Reclutamiento
        • CHU Toulouse - Hopital Paule de Viguier /ID# 255609
    • Rhone
      • Bron, Rhone, Francia, 69500
        • Reclutamiento
        • Hospices Civils de Lyon - Hopital Femme Mere Enfant /ID# 255443
    • Central District
      • Petah Tikva, Central District, Israel, 4920235
        • Reclutamiento
        • Schneider Children's Medical Center /ID# 254950
    • Jerusalem
      • Jerusalem, Jerusalem, Israel, 91031
        • Reclutamiento
        • Shaare Zedek Medical Center /ID# 254951
      • Messina, Italia, 98125
        • Reclutamiento
        • Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044
    • Genova
      • Genoa, Genova, Italia, 16147
        • Reclutamiento
        • IRCCS Istituto Giannina Gaslini /ID# 255262
    • Napoli
      • Naples, Napoli, Italia, 80131
        • Reclutamiento
        • Azienda Ospedaliera Universitaria Federico II - Naples /ID# 255045
    • Roma
      • Rome, Roma, Italia, 00165
        • Reclutamiento
        • Ospedale Pediatrico Bambino Gesu /ID# 255043
    • Aichi-ken
      • Ōbu, Aichi-ken, Japón, 474-8710
        • Reclutamiento
        • Aichi Children's Health And Medical Center /ID# 272085
    • Chiba
      • Kashiwa-shi, Chiba, Japón, 277-0871
        • Reclutamiento
        • Tsujinaka Hospital - Kashiwanoha /ID# 268409
    • Fukuoka
      • Kurume-shi, Fukuoka, Japón, 830-0011
        • Reclutamiento
        • Kurume University Hospital /ID# 268418
    • Gunma
      • Maebashi, Gunma, Japón, 371-8511
        • Reclutamiento
        • Gunma University Hospital /ID# 270560
    • Kumamoto
      • Kumamoto, Kumamoto, Japón, 861-8520
        • Reclutamiento
        • Japanese Red Cross Kumamoto Hospital /ID# 268586
    • Osaka
      • Izumi-Shi, Osaka, Japón, 594-1101
        • Reclutamiento
        • Osaka Women's and Children's Hospital /ID# 268419
    • Saitama
      • Saitama-shi, Saitama, Japón, 330-8777
        • Reclutamiento
        • Saitama Children's Medical Center /ID# 268410
    • Tokyo
      • Bunkyo-ku, Tokyo, Japón, 113-8519
        • Reclutamiento
        • Institute of Science Tokyo Hospital /ID# 269175
      • Fuchu-shi, Tokyo, Japón, 183-8561
        • Reclutamiento
        • Tokyo Metropolitan Children's Medical Center /ID# 268415
      • Setagaya City, Tokyo, Japón, 157-8535
        • Reclutamiento
        • National Center For Child Health And Development /ID# 268420
    • North Holland
      • Amsterdam, North Holland, Países Bajos, 1105 AZ
        • Reclutamiento
        • Amsterdam University Medical Center /ID# 254827
    • Kuyavian-Pomeranian Voivodeship
      • Torun, Kuyavian-Pomeranian Voivodeship, Polonia, 87-100
        • Terminado
        • Gastromed Sp. z o.o /ID# 255939
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polonia, 04-730
        • Reclutamiento
        • Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938
    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100045
        • Reclutamiento
        • Beijing Children's Hospital /ID# 256081
      • Beijing, Beijing Municipality, Porcelana, 100191
        • Reclutamiento
        • Peking University Third Hospital /ID# 255876
        • Contacto:
          • Site Coordinator
          • Número de teléfono: +86 010-82266699
    • Guangdong
      • Guangzhou, Guangdong, Porcelana, 510620
        • Reclutamiento
        • Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428
      • Guangzhou, Guangdong, Porcelana, 510655
        • Reclutamiento
        • The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589
    • Henan
      • Zhengzhou, Henan, Porcelana, 450018
        • Reclutamiento
        • Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562
    • Hunan
      • Changsha, Hunan, Porcelana, 410007
        • Reclutamiento
        • Hunan Children's Hospital /ID# 255610
    • Jiangxi
      • Nanchang, Jiangxi, Porcelana, 330006
        • Reclutamiento
        • Jiangxi Provincial Children's Hospital /ID# 255564
    • Liaoning
      • Shenyang, Liaoning, Porcelana, 110022
        • Reclutamiento
        • Shengjing Hospital of China Medical University /ID# 255563
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Porcelana, 200062
        • Reclutamiento
        • Children's Hospital of Shanghai /ID# 255531
      • Shanghai, Shanghai Municipality, Porcelana, 200065
        • Reclutamiento
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688
      • Dorado, Puerto Rico, 00646
        • Reclutamiento
        • Puerto Rico Health Institute /ID# 255071
      • San Juan, Puerto Rico, 00909-1711
        • Reclutamiento
        • Clinical Research Puerto Rico /ID# 266479
      • Birmingham, Reino Unido, B4 6NH
        • Reclutamiento
        • Birmingham Women's and Children's NHS Foundation Trust /ID# 255759
    • England
      • Sheffield, England, Reino Unido, S10 2TH
        • Reclutamiento
        • Sheffield Children's Hospital NHS Foundation Trust /ID# 255758
        • Contacto:
          • Site Coordinator
          • Número de teléfono: +44 114 273 0522
    • Greater London
      • London, Greater London, Reino Unido, E1 2ES
        • Reclutamiento
        • Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757
    • Stockholm County
      • Stockholm, Stockholm County, Suecia, 118 83
        • Reclutamiento
        • Sodersjukhuset /ID# 255239
      • Stockholm, Stockholm County, Suecia, 171 76
        • Reclutamiento
        • Astrid Lindgrens Barnsjukhus /ID# 255240
    • Västra Götaland County
      • Gothenburg, Västra Götaland County, Suecia, 413 46
        • Reclutamiento
        • Sahlgrenska Universitetssjukhuset /ID# 255236
        • Contacto:
          • Site Coordinator
          • Número de teléfono: +46313435865
      • Bern, Suiza, 3010
        • Reclutamiento
        • Inselspital, Universitaetsspital Bern /ID# 255321
    • Canton of Zurich
      • Zurich, Canton of Zurich, Suiza, 8032
        • Reclutamiento
        • Kinderspital Zurich - Eleonorenstiftung /ID# 255337
      • Changhua City, Changhua County, Taiwán, 50006
        • Reclutamiento
        • Changhua Christian Hospital /ID# 256082
      • Taipei, Taiwán, 100
        • Reclutamiento
        • National Taiwan University Hospital /ID# 255679
      • Ankara, Turquía (Türkiye), 06560
        • Reclutamiento
        • Gazi University Medical Faculty /ID# 255086
      • Istanbul, Turquía (Türkiye), 34453
        • Reclutamiento
        • Sariyer Hamidiye Etfal Egitim Ve Araştirma Hastanesi /ID# 257143
      • Istanbul, Turquía (Türkiye), 34899
        • Reclutamiento
        • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020
      • Kocaeli, Turquía (Türkiye), 41380
        • Reclutamiento
        • Kocaeli University Med Faculty /ID# 256922

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

2 años a 17 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Pediatric individuals, 2 to < 18 years old
  • Must have moderately to severely active CD, as defined by the PCDAI score > 30 assessed at Baseline
  • Must have endoscopic evidence of mucosal inflammation as documented by the SES-CD of ≥ 6 for ileocolonic or colonic disease (or SES-CD of ≥ 4 for isolated ileal disease)
  • Demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates (This drug class is not sufficient for eligibility for subjects in France, Italy, Netherlands, Spain, and Sweden), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), IMMs, and/or biologic therapies

Exclusion Criteria:

  • History of hereditary fructose intolerance (a rare genetic condition) or an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class

  • Any of the following medical disorders:

    1. Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD.

    2. A diagnosis of CD prior to 2 years of age.

    3. A diagnosis or suspected diagnosis of a primary immunodeficiency.

    4. Currently known complications of CD such as:

      • Active abscess (abdominal or perianal);
      • Symptomatic bowel strictures;
      • > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum;
      • Fulminant colitis;
      • Toxic megacolon;
      • Or any other manifestation that might require surgery while enrolled in the study.
    5. Ostomy or ileoanal pouch.

    6. Diagnosis of short gut or short bowel syndrome.

    7. Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of >3 bowel resections.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: PK Cohort 1: SS3 Dose A

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 1: SS3 Dose B

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 2: SS1

Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 2: SS3 Dose A

Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 2: SS3 Dose B

Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI
Experimental: Expansion Cohort 3: SS3 Dose A

Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI
Experimental: Expansion Cohort 3: SS3 Dose B

Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 1: SS1

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 1: SS2 Dose A

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 1: SS2 Dose B

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 2: SS2 Dose A

Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI
Experimental: PK Cohort 2: SS2 Dose B

Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI
Experimental: Expansion Cohort 3: SS1

Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI
Experimental: Expansion Cohort 3: SS2 Dose A

Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI
Experimental: Expansion Cohort 3: SS2 Dose B

Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

Otros nombres:
  • ABBV-066
  • SKYRIZI

Subcutaneous (SC) Injection

Otros nombres:
  • ABBV-066
  • SKYRIZI

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission
Periodo de tiempo: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 64 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD)
Periodo de tiempo: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 64 weeks
Cohorts 1 & 2: Maximum Observed Serum Concentration (Cmax) of Risankizumab
Periodo de tiempo: Up to approximately Week 64

Cmax of risankizumab

Up to approximately Week 64
Cohorts 1 & 2: Time to Cmax (Tmax) of Risankizumab
Periodo de tiempo: Up to approximately 64 weeks

Tmax of risankizumab

Up to approximately 64 weeks
Cohorts 1 & 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Risankizumab
Periodo de tiempo: Up to approximately 64 weeks

AUCtau of risankizumab

Up to approximately 64 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cohort 3 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Periodo de tiempo: At 12 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 12 weeks
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Periodo de tiempo: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 12 weeks
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Periodo de tiempo: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 12 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Periodo de tiempo: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 64 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Periodo de tiempo: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving PCDAI Clinical Remission
Periodo de tiempo: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per SES-CD
Periodo de tiempo: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 64 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
Periodo de tiempo: At 12 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 12 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
Periodo de tiempo: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 12 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Periodo de tiempo: At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 12 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
Periodo de tiempo: At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
Periodo de tiempo: At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.

At 64 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: ABBVIE INC., AbbVie

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

11 de diciembre de 2023

Finalización primaria (Estimado)

1 de abril de 2029

Finalización del estudio (Estimado)

1 de abril de 2029

Fechas de registro del estudio

Enviado por primera vez

10 de agosto de 2023

Primero enviado que cumplió con los criterios de control de calidad

10 de agosto de 2023

Publicado por primera vez (Actual)

16 de agosto de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • M16-194
  • 2022-502050-14-00 (Otro identificador: EU CT)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Marco de tiempo para compartir IPD

For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Criterios de acceso compartido de IPD

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir